Nkarta (NKTX) Cash from Financing Activities (2019 - 2026)
Nkarta's (NKTX) quarterly Cash from Financing Activities came in at $6000.0 in Q1 2026, down 90.62% quarter-over-quarter from $64000.0 in Q4 2025.
Nkarta (NKTX) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Nkarta's Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $6000.0 for Q1 2026.
- On a quarterly basis, Cash from Financing Activities changed N/A year-over-year to $6000.0 in Q1 2026; TTM through Mar 2026 was $147000.0, a 180.77% increase from a year earlier, with the FY2025 full-year figure at $141000.0, down 99.94% from the prior year.
- Cash from Financing Activities retreated to $6000.0 in Q1 2026 per NKTX's latest filing, from $64000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $226.3 million in Q1 2024 and bottomed at -$368000.0 in Q2 2024.
- The 5-year median for Cash from Financing Activities is $131500.0 (2022), against an average of $31.9 million.
- Biggest YoY gain for Cash from Financing Activities was 22626500.0% in 2024; the steepest drop was 193.16% in 2024.
- Year by year, Cash from Financing Activities stood at $424000.0 in 2022, then slumped by 30.42% to $295000.0 in 2023, then sank by 37.63% to $184000.0 in 2024, then plunged by 65.22% to $64000.0 in 2025, then sank by 90.62% to $6000.0 in 2026.
- Per Business Quant, the three latest NKTX Cash from Financing Activities figures stand at $6000.0 (Q1 2026), $64000.0 (Q4 2025), and $77000.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Nkarta | 170.79 Mn | 170.79 Mn | - | 6,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6,000.00 |
| Mar 31, 2026 | 6,000.00 |
| Dec 31, 2025 | 64,000.00 |
| Dec 31, 2025 | 64,000.00 |
| Jun 30, 2025 | 77,000.00 |
| Jun 30, 2025 | 77,000.00 |
| Dec 31, 2024 | 184,000.00 |
| Dec 31, 2024 | 184,000.00 |
| Sep 30, 2024 | 2,000.00 |
| Sep 30, 2024 | 2,000.00 |
| Jun 30, 2024 | -368,000.00 |
| Jun 30, 2024 | -368,000.00 |
| Mar 31, 2024 | 226.27 Mn |
| Mar 31, 2024 | 226.27 Mn |
| Dec 31, 2023 | 295,000.00 |
| Dec 31, 2023 | 295,000.00 |
| Jun 30, 2023 | 395,000.00 |
| Jun 30, 2023 | 395,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Mar 31, 2023 | 1,000.00 |